Biogen Inc. (BIIB) shareholders
Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (12.40%) | 18,294,524 | 12.40% | 13G (passive) amendment | Jun 30, 2026 |
| Primecap Management Co/Ca/ | 14,954,697 | 10.20% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 12,506,681 | 8.50% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 10,989,562 | 7.48% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 7,570,589 | 5.10% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BIIB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 18,217,239 | 12.32% | $3.94B | +5,409,698 | 0.17% |
| BlackRock, Inc. | 15,985,736 | 10.81% | $3.45B | +11,135 | 0.05% |
| Primecap Management Co/Ca/ | 15,154,606 | 10.25% | $3.27B | +396,999 | 1.94% |
| Vanguard Capital Management LLC | 9,651,117 | 6.53% | $2.09B | +113,700 | 0.04% |
| State Street Corp | 7,344,327 | 4.97% | $1.59B | +176,405 | 0.05% |
| Vanguard Portfolio Management LLC | 6,604,936 | 4.47% | $1.43B | +73,209 | 0.06% |
| Geode Capital Management, LLC | 4,449,295 | 3.01% | $957.94M | +106,693 | 0.05% |
| Wellington Management Group Llp | 3,117,469 | 2.11% | $673.56M | +155,828 | 0.12% |
| Norges Bank | 2,580,033 | 1.75% | $557.44M | New | 0.06% |
| Morgan Stanley | 2,411,271 | 1.63% | $520.98M | +240,331 | 0.03% |
| Aqr Capital Management LLC | 1,936,859 | 1.31% | $416.93M | +13,302 | 0.15% |
| JPMorgan Chase & Co | 1,823,140 | 1.23% | $394.95M | −192,869 | 0.02% |
| Invesco Ltd. | 1,803,944 | 1.22% | $389.76M | +58,689 | 0.03% |
| Amundi | 1,516,831 | 1.03% | $327.73M | +726,004 | 0.08% |
| Legal & General Group Plc | 1,493,289 | 1.01% | $322.64M | +143,457 | 0.07% |
| Northern Trust Corp | 1,429,490 | 0.97% | $308.86M | −17,089 | 0.04% |
| Boston Partners | 1,263,429 | 0.85% | $272.85M | −436,649 | 0.24% |
| UBS Asset Management Americas Inc | 1,255,168 | 0.85% | $271.19M | −122,400 | 0.05% |
| Goldman Sachs Group Inc | 1,230,390 | 0.83% | $265.84M | +179,296 | 0.02% |
| Dimensional Fund Advisors LP | 1,148,568 | 0.78% | $248.17M | +69,449 | 0.04% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,041 | 142M | 96.2% | 126 / 426 | 293 / 83 | 16M | 9M |
| Q1 2026 | 1,012 | 135M | 91.3% | 137 / 401 | 291 / 107 | 28M | 16M |
| Q4 2025 | 1,001 | 141M | 95.4% | 190 / 322 | 299 / 81 | 22M | 13M |
| Q3 2025 | 908 | 133M | 89.7% | 124 / 323 | 269 / 74 | 13M | 11M |
| Q2 2025 | 867 | 131M | 88.4% | 96 / 342 | 264 / 100 | 13M | 12M |
| Q1 2025 | 882 | 130M | 87.9% | 125 / 331 | 274 / 106 | 10M | 13M |
| Q4 2024 | 876 | 133M | 89.6% | 132 / 299 | 323 / 159 | 17M | 19M |
| Q3 2024 | 918 | 135M | 91.5% | 101 / 271 | 378 / 118 | 26M | 10M |
| Q2 2024 | 944 | 134M | 90.5% | 101 / 323 | 336 / 97 | 8M | 12M |
| Q1 2024 | 953 | 138M | 93.3% | 105 / 302 | 355 / 146 | 12M | 10M |
| Q4 2023 | 1,003 | 136M | 92.0% | 136 / 286 | 376 / 81 | 18M | 7M |
| Q3 2023 | 965 | 125M | 84.8% | 91 / 333 | 346 / 119 | 8M | 8M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
771 funds held BIIB in Q2 2026, 39% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BIIB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Primecap Fund | 8,359,880 | 5.66% | $1.81B | 1.88% | Jun 30, 2026 |
| Fidelity Contrafund | 4,988,655 | 3.37% | $1.08B | 0.60% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,687,985 | 3.17% | $1.01B | 0.04% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 3,827,862 | 2.59% | $827.05M | 0.05% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 3,199,078 | 2.16% | $691.19M | 0.31% | Jun 30, 2026 |
| Vanguard Health Care Fund | 2,745,486 | 1.86% | $557.20M | 1.46% | Jul 31, 2026 |
| Vanguard Capital Opportunity Fund | 2,624,317 | 1.78% | $567.01M | 1.73% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 2,031,041 | 1.37% | $438.83M | 0.05% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 2,027,406 | 1.37% | $397.37M | 0.16% | May 31, 2026 |
| Fidelity 500 Index Fund | 1,878,080 | 1.27% | $368.10M | 0.04% | May 31, 2026 |
| Vanguard Value Index Fund | 1,403,950 | 0.95% | $303.34M | 0.12% | Jun 30, 2026 |
| Vanguard Primecap Core Fund | 1,316,936 | 0.89% | $284.54M | 1.57% | Jun 30, 2026 |
| Fidelity Contrafund K6 | 1,075,723 | 0.73% | $232.42M | 0.62% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 1,042,998 | 0.71% | $225.35M | 0.56% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,037,164 | 0.70% | $224.09M | 2.47% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christopher Viehbacher | President and CEO, Director | 21,095 | 0.01% | Feb 17, 2026 |
| Jane Grogan | Head of Research | 4,408 | 0.00% | Nov 2, 2026 |
| Sean Godbout | Chief Accounting Officer | 1,459 | 0.00% | Oct 5, 2026 |
| Michael Parini | Chief Legal Officer | – | – | Sep 3, 2026 |
| Adam Keeney | Head of Corporate Development | 6,365 | 0.00% | May 5, 2026 |
| Robin Kramer | Chief Financial Officer | 9,024 | 0.01% | Feb 17, 2026 |
| Susan H. Alexander | EVP Chief Legal Officer | 58,537 | 0.04% | Feb 17, 2026 |
| Ginger Gregory | EVP, Human Resources | 22,359 | 0.02% | Feb 17, 2026 |
| Priya Singhal | Head of Development | 8,043 | 0.01% | Feb 17, 2026 |
| Rachid Izzar | Head of Global Product Strat. | 11,786 | 0.01% | Feb 17, 2026 |
| Nicole Murphy | Head of Pharm Ops and Tech | 19,611 | 0.01% | Feb 17, 2026 |
| Michael R. McDonnell | EVP, Chief Financial Officer | 24,341 | 0.02% | Feb 12, 2025 |
| Lloyd Minor | Director | 2,689 | 0.00% | Aug 5, 2026 |
| Maria C. Freire | Director | 8,820 | 0.01% | Jun 11, 2026 |
| Jesus B. Mantas | Director | 11,263 | 0.01% | Jun 11, 2026 |
| Menelas N. Pangalos | Director | 3,875 | 0.00% | Jun 11, 2026 |
| Stephen A. Sherwin | Director | 15,193 | 0.01% | Jun 11, 2026 |
| William A. Hawkins | Director | 10,365 | 0.01% | Jun 11, 2026 |
| Susan Langer | Director | 6,634 | 0.00% | Jun 11, 2026 |
| Monish D. Patolawala | Director | 5,215 | 0.00% | Jun 11, 2026 |
| Eric K. Rowinsky | Director | 25,844 | 0.02% | Jun 11, 2026 |
| Caroline Dorsa | Director | 31,002 | 0.02% | Jun 18, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jane Grogan Head of Research | Oct 30, 2026 | Tax withholding | −345 | $253.62 | $87.50K | 4,408 |
| Jane Grogan Head of Research | Oct 30, 2026 | Option exercise | +695 | – | – | 4,753 |
| Sean Godbout Chief Accounting Officer | Oct 2, 2026 | Tax withholding | −8 | $219.88 | $1.76K | 1,459 |
| Sean Godbout Chief Accounting Officer | Oct 2, 2026 | Option exercise | +27 | – | – | 1,467 |
| Lloyd Minor Director | Aug 4, 2026 | Sale(10b5-1 plan) | −593 | $200.96 | $119.17K | 2,689 |
| Lloyd Minor Director | Aug 3, 2026 | Sale(10b5-1 plan) | −593 | $203.34 | $120.58K | 3,282 |
| Maria C. Freire Director | Jun 9, 2026 | Award | +2,005 | – | – | 8,820 |
| Stephen A. Sherwin Director | Jun 9, 2026 | Award | +1,505 | – | – | 15,193 |
| Monish D. Patolawala Director | Jun 9, 2026 | Award | +1,505 | – | – | 5,215 |
| Jesus B. Mantas Director | Jun 9, 2026 | Award | +1,505 | – | – | 11,263 |
| Susan Langer Director | Jun 9, 2026 | Award | +1,505 | – | – | 6,634 |
| Lloyd Minor Director | Jun 9, 2026 | Award | +1,505 | – | – | 3,875 |
| Eric K. Rowinsky Director | Jun 9, 2026 | Award | +1,505 | – | – | 25,844 |
| Menelas N. Pangalos Director | Jun 9, 2026 | Award | +1,505 | – | – | 3,875 |
| Menelas N. Pangalos Director | Jun 9, 2026 | Option exercise | +2,370 | – | – | 2,370 |
| William A. Hawkins Director | Jun 9, 2026 | Award | +1,505 | – | – | 10,365 |
| Adam Keeney Head of Corporate Development | May 1, 2026 | Tax withholding | −455 | $187.06 | $85.11K | 6,365 |
| Adam Keeney Head of Corporate Development | May 1, 2026 | Option exercise | +939 | – | – | 6,820 |
| Sean Godbout Chief Accounting Officer | Apr 1, 2026 | Option exercise | +181 | – | – | 1,396 |
| Sean Godbout Chief Accounting Officer | Apr 1, 2026 | Tax withholding | −54 | $183.78 | $9.92K | 1,342 |
| Nicole Murphy Head of Pharm Ops and Tech | Feb 12, 2026 | Buy | +3 | $195.04 | $585 | 19,611 |
| Priya Singhal Head of Development | Feb 9, 2026 | Sale(10b5-1 plan) | −2,660 | $199.83 | $531.55K | 8,043 |
| Christopher Viehbacher President and CEO, Director | Feb 6, 2026 | Tax withholding | −4,356 | $201.18 | $876.34K | 21,095 |
| Christopher Viehbacher President and CEO, Director | Feb 6, 2026 | Option exercise | +15,453 | – | – | 36,548 |
| Christopher Viehbacher President and CEO, Director | Feb 6, 2026 | Tax withholding | −6,624 | $201.18 | $1.33M | 29,924 |
| Christopher Viehbacher President and CEO, Director | Feb 6, 2026 | Option exercise | +9,008 | – | – | 25,451 |
| Nicole Murphy Head of Pharm Ops and Tech | Feb 6, 2026 | Option exercise | +4,683 | – | – | 21,016 |
| Nicole Murphy Head of Pharm Ops and Tech | Feb 6, 2026 | Option exercise | +2,102 | – | – | 16,324 |
| Nicole Murphy Head of Pharm Ops and Tech | Feb 6, 2026 | Tax withholding | −1,017 | $201.18 | $204.60K | 15,307 |
| Nicole Murphy Head of Pharm Ops and Tech | Feb 6, 2026 | Option exercise | +1,940 | – | – | 17,247 |
| Nicole Murphy Head of Pharm Ops and Tech | Feb 6, 2026 | Tax withholding | −914 | $201.18 | $183.88K | 16,333 |
| Nicole Murphy Head of Pharm Ops and Tech | Feb 6, 2026 | Tax withholding | −1,408 | $201.18 | $283.26K | 19,608 |
| Jane Grogan Head of Research | Feb 6, 2026 | Option exercise | +1,385 | – | – | 3,176 |
| Jane Grogan Head of Research | Feb 6, 2026 | Tax withholding | −407 | $201.18 | $81.88K | 2,769 |
| Jane Grogan Head of Research | Feb 6, 2026 | Option exercise | +1,873 | – | – | 4,642 |
| Jane Grogan Head of Research | Feb 6, 2026 | Tax withholding | −584 | $201.18 | $117.49K | 4,058 |
| Susan H. Alexander EVP Chief Legal Officer | Feb 6, 2026 | Option exercise | +2,190 | – | – | 38,455 |
| Susan H. Alexander EVP Chief Legal Officer | Feb 6, 2026 | Tax withholding | −1,059 | $201.18 | $213.05K | 37,396 |
| Susan H. Alexander EVP Chief Legal Officer | Feb 6, 2026 | Option exercise | +1,940 | – | – | 39,336 |
| Susan H. Alexander EVP Chief Legal Officer | Feb 6, 2026 | Tax withholding | −931 | $201.18 | $187.30K | 38,405 |
| Susan H. Alexander EVP Chief Legal Officer | Feb 6, 2026 | Tax withholding | −1,514 | $201.18 | $304.59K | 41,807 |
| Susan H. Alexander EVP Chief Legal Officer | Feb 6, 2026 | Option exercise | +4,916 | – | – | 43,321 |
| Adam Keeney Head of Corporate Development | Feb 6, 2026 | Tax withholding | −589 | $201.18 | $118.50K | 3,597 |
| Adam Keeney Head of Corporate Development | Feb 6, 2026 | Option exercise | +1,802 | – | – | 4,186 |
| Adam Keeney Head of Corporate Development | Feb 6, 2026 | Option exercise | +3,278 | – | – | 6,875 |
| Adam Keeney Head of Corporate Development | Feb 6, 2026 | Tax withholding | −994 | $201.18 | $199.97K | 5,881 |
| Robin Kramer Chief Financial Officer | Feb 6, 2026 | Tax withholding | −207 | $201.18 | $41.64K | 9,024 |
| Robin Kramer Chief Financial Officer | Feb 6, 2026 | Option exercise | +789 | – | – | 8,801 |
| Robin Kramer Chief Financial Officer | Feb 6, 2026 | Tax withholding | −273 | $201.18 | $54.92K | 8,528 |
| Robin Kramer Chief Financial Officer | Feb 6, 2026 | Tax withholding | −1,063 | $201.18 | $213.85K | 11,472 |
| Robin Kramer Chief Financial Officer | Feb 6, 2026 | Option exercise | +3,511 | – | – | 12,535 |
| Robin Kramer Chief Financial Officer | Feb 6, 2026 | Option exercise | +703 | – | – | 9,231 |
| Priya Singhal Head of Development | Feb 6, 2026 | Tax withholding | −1,056 | $201.18 | $212.45K | 7,432 |
| Priya Singhal Head of Development | Feb 6, 2026 | Option exercise | +4,683 | – | – | 12,115 |
| Priya Singhal Head of Development | Feb 6, 2026 | Tax withholding | −1,412 | $201.18 | $284.07K | 10,703 |
| Priya Singhal Head of Development | Feb 6, 2026 | Option exercise | +2,217 | – | – | 8,488 |
| Ginger Gregory EVP, Human Resources | Feb 6, 2026 | Tax withholding | −1,132 | $201.18 | $227.74K | 22,359 |
| Ginger Gregory EVP, Human Resources | Feb 6, 2026 | Tax withholding | −666 | $201.18 | $133.99K | 19,745 |
| Ginger Gregory EVP, Human Resources | Feb 6, 2026 | Option exercise | +1,802 | – | – | 20,411 |
| Ginger Gregory EVP, Human Resources | Feb 6, 2026 | Tax withholding | −791 | $201.18 | $159.13K | 18,609 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Biogen's stock actually held short. Settlement fails (shares not delivered on time) peaked at 49,163 shares on Sep 28, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lloyd Minor Director | Aug 4, 2026 | 593 | $119.17K | Aug 4, 2026 | Restricted Stock Vesting |
| Lloyd Minor Director | Aug 3, 2026 | 593 | $120.58K | Aug 3, 2026 | Restricted Stock Vesting |
| Priya Singhal Officer | Feb 9, 2026 | 2,660 | $531.55K | Feb 9, 2026 | Restricted Stock Vesting |
| Priya Singhal Officer | Feb 2, 2026 | 748 | $134.12K | Feb 2, 2026 | Restricted Stock Vesting |
| Priya Singhal Officer | Sep 2, 2025 | 517 | $69.05K | Sep 2, 2025 | Restricted Stock Vesting |
| Rachid Izzar Officer | Jul 8, 2025 | 2,223 | $300.11K | Jul 8, 2025 | Restricted Stock Vesting |
| Priya Singhal Officer | May 19, 2025 | 3,806 | $480.51K | May 19, 2025 | Restricted Stock Vesting |
| Stephen A. Sherwin Director | Mar 7, 2025 | 8,760 | $1.29M | Mar 7, 2025 | Restricted Stock Units |
| Priya Singhal Officer | Dec 9, 2024 | 110 | $17.29K | Dec 9, 2024 | Restricted Stock Vesting |
| Priya Singhal Officer | Sep 3, 2024 | 431 | $88.02K | Sep 3, 2024 | Restricted Stock Vesting |
| Priya Singhal Officer | Apr 2, 2024 | 93 | $19.82K | Apr 2, 2024 | ESPP Purchase |
| Priya Singhal Officer | Feb 22, 2024 | 262 | $57.96K | Feb 22, 2024 | Performance Shares |
| Priya Singhal Officer | Feb 21, 2024 | 108 | $23.92K | Feb 21, 2024 | Performance Shares |
| Priya Singhal Officer | Feb 12, 2024 | 419 | $100.33K | Feb 12, 2024 | Restricted Stock Vesting |
| Priya Singhal Officer | Feb 2, 2024 | 634 | $155.92K | Feb 2, 2024 | Restricted Stock Vesting |
Congress trades
40 trades in Biogen reported by 15 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Maria Elvira Salazar FL27 | Sold (part) | Sep 24, 2026 | $1K–15K | Oct 7, 2026 |
| Kevin Hern OK01 | Sold | Aug 18, 2026 | $1K–15K | Sep 1, 2026 |
| Gilbert Cisneros CA31 | Bought | Jun 5, 2026 | $1K–15K | Jul 2, 2026 |
| Maria Elvira Salazar FL27 | Sold | Jun 2, 2026 | $15K–50K | Jul 7, 2026 |
| Maria Elvira Salazar FL27 | Bought | May 12, 2026 | $1K–15K | Jun 8, 2026 |
| Maria Elvira Salazar FL27 | Bought | May 11, 2026 | $50K–100K | Jun 8, 2026 |
| Maria Elvira Salazar FL27 | Bought | May 11, 2026 | $1K–15K | Jun 8, 2026 |
| Gilbert Cisneros CA31 | Bought | Jan 30, 2026 | $1K–15K | Feb 13, 2026 |
| Rob Bresnahan PA08 | Bought | May 15, 2025 | $1K–15K | Jun 9, 2025 |
| Rob Bresnahan PA08 | Sold | Apr 8, 2025 | $1K–15K | May 8, 2025 |
| Rob Bresnahan PA08 | Bought | Feb 25, 2025 | $1K–15K | Mar 27, 2025 |
| Rohit Khanna CA17 · child | Sold | Apr 26, 2024 | $1K–15K | May 6, 2024 |
| Rohit Khanna CA17 · child | Bought | Dec 5, 2023 | $15K–50K | Jan 4, 2024 |
| Daniel Goldman NY10 | Sold (part) | Mar 6, 2023 | $1K–15K | Apr 17, 2023 |
| Shri Thanedar MI13 | Sold | Jan 23, 2023 | $15K–50K | Feb 9, 2023 |
| Kathy Manning NC06 · joint account | Sold | Aug 3, 2022 | $1K–15K | Sep 14, 2022 |
| Kathy Manning NC06 · joint account | Bought | Jul 20, 2022 | $1K–15K | Aug 10, 2022 |
| Josh Gottheimer NJ05 · joint account | Sold | Mar 17, 2022 | $1K–15K | Apr 17, 2022 |
| Kathy Manning NC06 · spouse | Sold | Jan 14, 2022 | $1K–15K | Feb 11, 2022 |
| Josh Gottheimer NJ05 · joint account | Bought | Jan 10, 2022 | $1K–15K | Feb 18, 2022 |
| Josh Gottheimer NJ05 · joint account | Sold (part) | Dec 9, 2021 | $1K–15K | Jan 10, 2022 |
| Josh Gottheimer NJ05 · joint account | Bought | Oct 18, 2021 | $1K–15K | Nov 15, 2021 |
| Josh Gottheimer NJ05 · joint account | Sold (part) | Sep 15, 2021 | $1K–15K | Oct 13, 2021 |
| Josh Gottheimer NJ05 · joint account | Bought | Jun 8, 2021 | $1K–15K | Jul 15, 2021 |
| Peter Meijer MI03 | Sold | Feb 16, 2021 | $15K | Mar 16, 2021 |
| Byron Donalds FL19 | Sold | Feb 2, 2021 | $1K–15K | Nov 8, 2024 1375 days late |
| Christopher L. Jacobs NY27 | Sold | Jan 4, 2021 | $1K–15K | Feb 17, 2021 |
| Gilbert Cisneros CA31 | Sold | Dec 22, 2020 | $1K–15K | Jan 11, 2021 |
| Gilbert Cisneros CA31 | Bought | Sep 16, 2020 | $1K–15K | Oct 14, 2020 |
| Josh Gottheimer NJ05 · joint account | Bought | Jul 7, 2020 | $1K–15K | Aug 10, 2020 |
| Gilbert Cisneros CA31 | Bought | Apr 29, 2020 | $1K–15K | May 13, 2020 |
| Gilbert Cisneros CA31 | Sold | Mar 18, 2020 | $1K–15K | Apr 16, 2020 |
| Gilbert Cisneros CA31 | Bought | Feb 7, 2020 | $1K–15K | Mar 10, 2020 |
| Dean Phillips MN03 | Sold (part) | Sep 11, 2019 | $1K–15K | Oct 11, 2019 |
| Dean Phillips MN03 | Sold (part) | Aug 13, 2019 | $1K–15K | Sep 16, 2019 |
| Donna Shalala FL27 | Sold | Jun 24, 2019 | $1K–15K | Apr 27, 2020 308 days late |
| Dean Phillips MN03 | Bought | Jun 20, 2019 | $1K–15K | Jul 11, 2019 |
| Dean Phillips MN03 | Sold (part) | May 13, 2019 | $1K–15K | Jun 13, 2019 |
| Gilbert Cisneros CA31 | Sold | May 9, 2019 | $1K–15K | Jun 18, 2019 |
| Nicholas Van Taylor TX03 · spouse | Sold | Mar 25, 2019 | $1K–15K | Apr 15, 2019 |
See a number that looks wrong?